glp·helper
glphelper.com/mounjaro/massachusetts/springfield
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® providers &
prescriptions in Springfield, MA

Verified Mounjaro providers in Springfield, MA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Mounjaro weight loss →trial-anchored estimate
city providers
37
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Massachusetts
37 of 37 shown

Find a Mounjaro provider in Massachusetts.

Every entry is checked against the NPI registry and the Massachusetts medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Massachusetts city · /mounjaro/massachusetts/{city}
§ 03Getting Mounjaro in Springfield
37 providers · Springfield, MA

How to get Mounjaro in Springfield.

37 GLP-1 prescribers and 7 local resource types are on record for Springfield, plus 3 nearby towns in the directory.

Prescribers in Springfield
37 prescribers
37 GLP-1 prescribers in Springfield, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (14), Family Medicine (12) and Internal Medicine (10). Any Massachusetts-licensed physician, nurse practitioner, or PA can prescribe Mounjaro, over video or in person. The nearest towns on record are Worcester (40 providers), Cambridge (43 providers) and Boston (44 providers).
Around the prescription in Springfield
7 listed nearby
6 dietitians, 1 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 3 physiotherapists and 6 places to move are on record near Springfield.
Medicaid (weight loss)
Limited
As of April 2026, Massachusetts Medicaid covers GLP-1s for weight loss only in limited cases (BMI 30+, or 27+ with a related condition; narrowing in July 2026). Diabetes coverage is broader. Employer and private plans vary by plan.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Massachusetts’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Zepbound is the FDA-approved tirzepatide for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Massachusetts

Diagnosed diabetes reaches 8.5% of adults in Massachusetts.

of Massachusetts adults have obesity
27%
diagnosed diabetes
8.5%

Age-adjusted estimates for Massachusetts, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight lossoral and sublingual GLP-1 options
§ 05Support around Mounjaro in Springfield
6 fitness clubs

The prescription is one part. Here is the rest, in Springfield.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Springfield, MA, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Spectacle Pond Recreation Area
REC CENTER
4.6 on Google · 317 reviews
2540 Boston Post Rd
Website
Club Fitness Enfield
FITNESS
4.2 on Google · 257 reviews
640 Enfield St
Website
Powerhouse Gym
FITNESS
4.4 on Google · 224 reviews
1452 Memorial Ave
Website
Powerhouse Gym Chicopee
FITNESS
4.3 on Google · 162 reviews
1501 Memorial Dr
Website
New England Functional Fitness
FITNESS
5.0 on Google · 125 reviews
168 Denslow Rd
Website
Next Fitness And Crossfit Catch
FITNESS
4.8 on Google · 99 reviews
470 Shoemaker Ln
Website

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Maryann Hayes, LDN
NUTRITIONIST
Nutritionist
3300 Main St
Call 413-794-7194NPI 1083827208
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8 to 2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Mounjaro weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Mounjaro cash price (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Mounjaro providers in Massachusetts

NPI-verified Mounjaro (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Mounjaro in other states

Find NPI-verified Mounjaro (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Mounjaro in Massachusetts

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]